Hyperthermic IntraVEsical Chemotherapy

Patient (N=259)Intermediate risk
NMIBC
TURB and 1 instillation MMC.
Screened, Consented Randomised
Hyperthermia 60mins +
Mitomycin C 40 mg
Once weekly for 6 weeks
Mitomycin C 40mg
Once weekly for 6 weeks
Year 1: 3-monthly surveillance for disease recurrence.
Year 2: 6-monthly surveillance for disease recurrence to 24 months.
Disease free survival

24 Months Follow Up
PEP: Disease Free Time, SEP: Recurrence Rate, Tolerance, QoL